Anastrozole is a potent, selective, non-steroidal aromatase inhibitor (AI). Reversibly inhibits the CYP19A1 (aromatase) enzyme which converts androgens (testosterone, androstenedione) to oestrogens (oestradiol, oestrone) in peripheral adipose tissue, adrenal glands, and breast tissue. At 1mg/day suppresses oestradiol >80% in postmenopausal women. Used in research to control oestrogen elevation during androgen administration and as reference AI in breast cancer models.
Also Known As
Anastrozole, ZD1033
Compound Class
Non-steroidal aromatase inhibitor (AI)
Molecular Formula
C₁₇H₁₉N₅
Molecular Weight
293.37 Da
CAS Number
120511-73-1
Half-Life
~40–50 hours
Research Applications
Aromatase Inhibition Research
Anastrozole at nanomolar concentrations inhibits aromatase with IC50 ~10 nM. Used as reference AI in CYP19A1 assays, oestrogen suppression dose-response studies, and aromatase expression models in breast, adipose, and bone tissue.
ER-Positive Breast Cancer Research
ATAC trial defined anastrozole vs tamoxifen in postmenopausal ER+ BC — anastrozole showed superior DFS. Reference compound for comparing aromatase inhibition to direct ER antagonism as breast cancer research strategies.
Oestrogen Control in Androgen Research
During testosterone administration models, aromatisation raises oestradiol causing negative feedback on HPG axis and potential gynecomastia. Anastrozole dose-response for oestrogen suppression during TRT research is well-characterised.
Bone Density Research
AI-induced oestrogen deprivation reduces BMD — anastrozole is reference compound for studying AI-related bone loss, a critical safety research area. Often paired with bone-protective compound research.
Key Research Data
Study / Source
Key Findings
ATAC Trial 2002/2010 Lancet
N=9,366: anastrozole vs tamoxifen postmenopausal ER+ BC — anastrozole superior DFS at 10-year follow-up, reference comparative data
Burnett-Bowie et al. 2009 JCEM
Anastrozole in hypogonadal men: oestrogen suppression raised testosterone via reduced negative feedback — HPG axis model data
AI bone loss meta-analysis 2012
Aromatase inhibitor therapy associated with 1-2% annual BMD reduction — anastrozole reference for bone research models
Arimidex (Anastrozole) is a Non-steroidal aromatase inhibitor (AI). Anastrozole is a potent, selective, non-steroidal aromatase inhibitor (AI). Reversibly inhibits the CYP19A1 (aromatase) enzyme which converts androgens (testosterone, androstenedione) to oestrogens (oestradiol, oestrone) in peripheral adipose tissue,…
How does Arimidex work in research models?
Anastrozole at nanomolar concentrations inhibits aromatase with IC50 ~10 nM. Used as reference AI in CYP19A1 assays, oestrogen suppression dose-response studies, and aromatase expression models in breast, adipose, and bone tissue….
What makes Arimidex different from similar compounds?
ATAC trial defined anastrozole vs tamoxifen in postmenopausal ER+ BC — anastrozole showed superior DFS. Reference compound for comparing aromatase inhibition to direct ER antagonism as breast cancer research strategies….
Does QSC ship Arimidex to the USA?
Yes. QSC Arimidex ships domestically across the USA and internationally to EU, UK, Canada, and Australia. Every batch carries a Janoshik third-party COA confirming ≥99% HPLC purity and MS identity verification.
